Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

Morten Karsdal; Thomas R. Cox; Amelia L. Parker; Nicholas Willumsen; Jannie Marie Bülow Sand; Gisli Jenkins; Henrik H. Hansen; Anouk Oldenburger; Kerstin E. Geillinger-kaestle; Anna Thorsø Larsen; Darcey Black; Federica Genovese; Alexander Eckersley; Andrea Heinz; Alexander Nyström; Signe Holm Nielsen; Lucas Bennink; Lars Johannsson; Anne-christine Bay-jensen; Dana E. Orange; Scott Friedman; Mads Røpke; Vincent Fiore; Detlef Schuppan; Florian Rieder; Benjamin Simona; Lee Borthwick; Mark Skarsfeldt; Haakan Wennbo; Paresh Thakker; Ruedi Stoffel; Graham W. Clarke; Raghu Kalluri; Darren Ruane; Faiez Zannad; Joachim Høg Mortensen; Dovile Sinkeviciute; Fred Sundberg; Molly Coseno; Christian Thudium; Adam P. Croft; Dinesh Khanna; Michael Cooreman; Andre Broermann; Diana Julie Leeming; Ali Mobasheri; Sylvie Ricard-blum

doi:10.3390/jcm14061856

Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

Morten Karsdal, Thomas R. Cox, Amelia L. Parker, Nicholas Willumsen, Jannie Marie Bülow Sand, Gisli Jenkins, Henrik H. Hansen, Anouk Oldenburger, Kerstin E. Geillinger-kaestle, Anna Thorsø Larsen, Darcey Black, Federica Genovese, Alexander Eckersley, Andrea Heinz, Alexander Nyström, Signe Holm Nielsen, Lucas Bennink, Lars Johannsson, Anne-christine Bay-jensen, Dana E. OrangeScott Friedman, Mads Røpke, Vincent Fiore, Detlef Schuppan, Florian Rieder, Benjamin Simona, Lee Borthwick, Mark Skarsfeldt, Haakan Wennbo, Paresh Thakker, Ruedi Stoffel, Graham W. Clarke, Raghu Kalluri, Darren Ruane, Faiez Zannad, Joachim Høg Mortensen, Dovile Sinkeviciute, Fred Sundberg, Molly Coseno, Christian Thudium, Adam P. Croft, Dinesh Khanna, Michael Cooreman, Andre Broermann, Diana Julie Leeming, Ali Mobasheri, Sylvie Ricard-blum

LEO Foundation Center for Cutaneous Drug Delivery

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

15 Citationer (Scopus)

24 Downloads (Pure)

Abstract

first_pagesettingsOrder Article Reprints
Open AccessReview
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics
by Morten Karsdal 1,*ORCID,Thomas R. Cox 2,3ORCID,Amelia L. Parker 2,3,Nicholas Willumsen 1,Jannie Marie Bülow Sand 1,Gisli Jenkins 4,Henrik H. Hansen 5ORCID,Anouk Oldenburger 6,Kerstin E. Geillinger-Kaestle 7,Anna Thorsø Larsen 1,Darcey Black 8ORCID,Federica Genovese 1ORCID,Alexander Eckersley 9ORCID,Andrea Heinz 10ORCID,Alexander Nyström 11ORCID,Signe Holm Nielsen 1ORCID,Lucas Bennink 12ORCID,Lars Johannsson 13,Anne-Christine Bay-Jensen 1ORCID,Dana E. Orange 14ORCID,add Show full author list
1
Nordic Bioscience, 2730 Herlev, Denmark
2
Garvan Institute of Medical Research, Sydney 2010, Australia
3
School of Clinical Medicine, St Vincent’s Clinical Campus, UNSW Medicine & Health, UNSW, Sydney 2010, Australia
4
Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London SW7 2AZ, UK
5
Gubra, 2970 Hørsholm, Denmark
6
Global Drug Discovery, Novo Nordisk, 2760 Maaloev, Denmark
7
Department of Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany
8
TherapeutAix UG, 52062 Aachen, Germany
9
Wellcome Centre for Cell Matrix Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK
10
LEO Foundation Center for Cutaneous Drug Delivery, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark

add Show full affiliation list
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(6), 1856; https://doi.org/10.3390/jcm14061856
Submission received: 20 December 2024 / Revised: 28 January 2025 / Accepted: 8 February 2025 / Published: 10 March 2025
(This article belongs to the Section Clinical Research Methods)
Downloadkeyboard_arrow_down Browse Figures Versions Notes

Abstract
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.

Originalsprog	Engelsk
Artikelnummer	1856
Tidsskrift	Journal of Clinical Medicine
Vol/bind	14
Udgave nummer	6
ISSN	2077-0383
DOI	https://doi.org/10.3390/jcm14061856
Status	Udgivet - 2025

Adgang til dokumentet

10.3390/jcm14061856Licens: CC BY

FulltextForlagets udgivne version, 1,77 MBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Karsdal, M., Cox, T. R., Parker, A. L., Willumsen, N., Sand, J. M. B., Jenkins, G., Hansen, H. H., Oldenburger, A., Geillinger-kaestle, K. E., Larsen, A. T., Black, D., Genovese, F., Eckersley, A., Heinz, A., Nyström, A., Holm Nielsen, S., Bennink, L., Johannsson, L., Bay-jensen, A., ... Ricard-blum, S. (2025). Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics. Journal of Clinical Medicine, 14(6), Artikel 1856. https://doi.org/10.3390/jcm14061856

Karsdal, M, Cox, TR, Parker, AL, Willumsen, N, Sand, JMB, Jenkins, G, Hansen, HH, Oldenburger, A, Geillinger-kaestle, KE, Larsen, AT, Black, D, Genovese, F, Eckersley, A, Heinz, A, Nyström, A, Holm Nielsen, S, Bennink, L, Johannsson, L, Bay-jensen, A, Orange, DE, Friedman, S, Røpke, M, Fiore, V, Schuppan, D, Rieder, F, Simona, B, Borthwick, L, Skarsfeldt, M, Wennbo, H, Thakker, P, Stoffel, R, Clarke, GW, Kalluri, R, Ruane, D, Zannad, F, Mortensen, JH, Sinkeviciute, D, Sundberg, F, Coseno, M, Thudium, C, Croft, AP, Khanna, D, Cooreman, M, Broermann, A, Leeming, DJ, Mobasheri, A & Ricard-blum, S 2025, 'Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics', Journal of Clinical Medicine, bind 14, nr. 6, 1856. https://doi.org/10.3390/jcm14061856

@article{7e80ab83585640fd835eea8e73f36a15,

title = "Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics",

abstract = "first_pagesettingsOrder Article ReprintsOpen AccessReviewAdvances in Extracellular Matrix-Associated Diagnostics and Therapeuticsby Morten Karsdal 1,*ORCID,Thomas R. Cox 2,3ORCID,Amelia L. Parker 2,3,Nicholas Willumsen 1,Jannie Marie B{\"u}low Sand 1,Gisli Jenkins 4,Henrik H. Hansen 5ORCID,Anouk Oldenburger 6,Kerstin E. Geillinger-Kaestle 7,Anna Thors{\o} Larsen 1,Darcey Black 8ORCID,Federica Genovese 1ORCID,Alexander Eckersley 9ORCID,Andrea Heinz 10ORCID,Alexander Nystr{\"o}m 11ORCID,Signe Holm Nielsen 1ORCID,Lucas Bennink 12ORCID,Lars Johannsson 13,Anne-Christine Bay-Jensen 1ORCID,Dana E. Orange 14ORCID,add Show full author list1Nordic Bioscience, 2730 Herlev, Denmark2Garvan Institute of Medical Research, Sydney 2010, Australia3School of Clinical Medicine, St Vincent{\textquoteright}s Clinical Campus, UNSW Medicine & Health, UNSW, Sydney 2010, Australia4Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London SW7 2AZ, UK5Gubra, 2970 H{\o}rsholm, Denmark6Global Drug Discovery, Novo Nordisk, 2760 Maaloev, Denmark7Department of Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany8TherapeutAix UG, 52062 Aachen, Germany9Wellcome Centre for Cell Matrix Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK10LEO Foundation Center for Cutaneous Drug Delivery, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark add Show full affiliation list*Author to whom correspondence should be addressed.J. Clin. Med. 2025, 14(6), 1856; https://doi.org/10.3390/jcm14061856Submission received: 20 December 2024 / Revised: 28 January 2025 / Accepted: 8 February 2025 / Published: 10 March 2025(This article belongs to the Section Clinical Research Methods)Downloadkeyboard_arrow_down Browse Figures Versions NotesAbstractThe extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM{\textquoteright}s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.",

author = "Morten Karsdal and Cox, {Thomas R.} and Parker, {Amelia L.} and Nicholas Willumsen and Sand, {Jannie Marie B{\"u}low} and Gisli Jenkins and Hansen, {Henrik H.} and Anouk Oldenburger and Geillinger-kaestle, {Kerstin E.} and Larsen, {Anna Thors{\o}} and Darcey Black and Federica Genovese and Alexander Eckersley and Andrea Heinz and Alexander Nystr{\"o}m and {Holm Nielsen}, Signe and Lucas Bennink and Lars Johannsson and Anne-christine Bay-jensen and Orange, {Dana E.} and Scott Friedman and Mads R{\o}pke and Vincent Fiore and Detlef Schuppan and Florian Rieder and Benjamin Simona and Lee Borthwick and Mark Skarsfeldt and Haakan Wennbo and Paresh Thakker and Ruedi Stoffel and Clarke, {Graham W.} and Raghu Kalluri and Darren Ruane and Faiez Zannad and Mortensen, {Joachim H{\o}g} and Dovile Sinkeviciute and Fred Sundberg and Molly Coseno and Christian Thudium and Croft, {Adam P.} and Dinesh Khanna and Michael Cooreman and Andre Broermann and Leeming, {Diana Julie} and Ali Mobasheri and Sylvie Ricard-blum",

year = "2025",

doi = "10.3390/jcm14061856",

language = "English",

volume = "14",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "M D P I AG",

number = "6",

}

TY - JOUR

T1 - Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

AU - Karsdal, Morten

AU - Cox, Thomas R.

AU - Parker, Amelia L.

AU - Willumsen, Nicholas

AU - Sand, Jannie Marie Bülow

AU - Jenkins, Gisli

AU - Hansen, Henrik H.

AU - Oldenburger, Anouk

AU - Geillinger-kaestle, Kerstin E.

AU - Larsen, Anna Thorsø

AU - Black, Darcey

AU - Genovese, Federica

AU - Eckersley, Alexander

AU - Heinz, Andrea

AU - Nyström, Alexander

AU - Holm Nielsen, Signe

AU - Bennink, Lucas

AU - Johannsson, Lars

AU - Bay-jensen, Anne-christine

AU - Orange, Dana E.

AU - Friedman, Scott

AU - Røpke, Mads

AU - Fiore, Vincent

AU - Schuppan, Detlef

AU - Rieder, Florian

AU - Simona, Benjamin

AU - Borthwick, Lee

AU - Skarsfeldt, Mark

AU - Wennbo, Haakan

AU - Thakker, Paresh

AU - Stoffel, Ruedi

AU - Clarke, Graham W.

AU - Kalluri, Raghu

AU - Ruane, Darren

AU - Zannad, Faiez

AU - Mortensen, Joachim Høg

AU - Sinkeviciute, Dovile

AU - Sundberg, Fred

AU - Coseno, Molly

AU - Thudium, Christian

AU - Croft, Adam P.

AU - Khanna, Dinesh

AU - Cooreman, Michael

AU - Broermann, Andre

AU - Leeming, Diana Julie

AU - Mobasheri, Ali

AU - Ricard-blum, Sylvie

PY - 2025

Y1 - 2025

N2 - first_pagesettingsOrder Article ReprintsOpen AccessReviewAdvances in Extracellular Matrix-Associated Diagnostics and Therapeuticsby Morten Karsdal 1,*ORCID,Thomas R. Cox 2,3ORCID,Amelia L. Parker 2,3,Nicholas Willumsen 1,Jannie Marie Bülow Sand 1,Gisli Jenkins 4,Henrik H. Hansen 5ORCID,Anouk Oldenburger 6,Kerstin E. Geillinger-Kaestle 7,Anna Thorsø Larsen 1,Darcey Black 8ORCID,Federica Genovese 1ORCID,Alexander Eckersley 9ORCID,Andrea Heinz 10ORCID,Alexander Nyström 11ORCID,Signe Holm Nielsen 1ORCID,Lucas Bennink 12ORCID,Lars Johannsson 13,Anne-Christine Bay-Jensen 1ORCID,Dana E. Orange 14ORCID,add Show full author list1Nordic Bioscience, 2730 Herlev, Denmark2Garvan Institute of Medical Research, Sydney 2010, Australia3School of Clinical Medicine, St Vincent’s Clinical Campus, UNSW Medicine & Health, UNSW, Sydney 2010, Australia4Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London SW7 2AZ, UK5Gubra, 2970 Hørsholm, Denmark6Global Drug Discovery, Novo Nordisk, 2760 Maaloev, Denmark7Department of Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany8TherapeutAix UG, 52062 Aachen, Germany9Wellcome Centre for Cell Matrix Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK10LEO Foundation Center for Cutaneous Drug Delivery, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark add Show full affiliation list*Author to whom correspondence should be addressed.J. Clin. Med. 2025, 14(6), 1856; https://doi.org/10.3390/jcm14061856Submission received: 20 December 2024 / Revised: 28 January 2025 / Accepted: 8 February 2025 / Published: 10 March 2025(This article belongs to the Section Clinical Research Methods)Downloadkeyboard_arrow_down Browse Figures Versions NotesAbstractThe extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.

AB - first_pagesettingsOrder Article ReprintsOpen AccessReviewAdvances in Extracellular Matrix-Associated Diagnostics and Therapeuticsby Morten Karsdal 1,*ORCID,Thomas R. Cox 2,3ORCID,Amelia L. Parker 2,3,Nicholas Willumsen 1,Jannie Marie Bülow Sand 1,Gisli Jenkins 4,Henrik H. Hansen 5ORCID,Anouk Oldenburger 6,Kerstin E. Geillinger-Kaestle 7,Anna Thorsø Larsen 1,Darcey Black 8ORCID,Federica Genovese 1ORCID,Alexander Eckersley 9ORCID,Andrea Heinz 10ORCID,Alexander Nyström 11ORCID,Signe Holm Nielsen 1ORCID,Lucas Bennink 12ORCID,Lars Johannsson 13,Anne-Christine Bay-Jensen 1ORCID,Dana E. Orange 14ORCID,add Show full author list1Nordic Bioscience, 2730 Herlev, Denmark2Garvan Institute of Medical Research, Sydney 2010, Australia3School of Clinical Medicine, St Vincent’s Clinical Campus, UNSW Medicine & Health, UNSW, Sydney 2010, Australia4Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London SW7 2AZ, UK5Gubra, 2970 Hørsholm, Denmark6Global Drug Discovery, Novo Nordisk, 2760 Maaloev, Denmark7Department of Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany8TherapeutAix UG, 52062 Aachen, Germany9Wellcome Centre for Cell Matrix Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK10LEO Foundation Center for Cutaneous Drug Delivery, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark add Show full affiliation list*Author to whom correspondence should be addressed.J. Clin. Med. 2025, 14(6), 1856; https://doi.org/10.3390/jcm14061856Submission received: 20 December 2024 / Revised: 28 January 2025 / Accepted: 8 February 2025 / Published: 10 March 2025(This article belongs to the Section Clinical Research Methods)Downloadkeyboard_arrow_down Browse Figures Versions NotesAbstractThe extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.

U2 - 10.3390/jcm14061856

DO - 10.3390/jcm14061856

M3 - Journal article

C2 - 40142664

SN - 2077-0383

VL - 14

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 6

M1 - 1856

ER -